Cue Biopharma, Inc. (CUE) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up 1% as Saudi Arabian refinery attack reignites supply concerns
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
- Seagate Technology (STX) Tops Q1 EPS by 29c, Offers Guidance
Cue Biopharma (CUE) PT Lowered to $4 at Jefferies
November 15, 2024 8:59 AM ESTJefferies analyst Maury Raycroft lowered the price target on Cue Biopharma (NASDAQ: CUE) to $4.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Stock has surged ~230% following CUE's recent $12M capital raise. However, the cash overhang still remains ($32M), limiting cos ability to... More



